MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen

Male 0301 basic medicine Mediator Complex Prostate Prostatic Neoplasms Acetylation Androgen Antagonists QH426-470 16. Peace & justice 3. Good health Gene Expression Regulation, Neoplastic 03 medical and health sciences Receptors, Androgen Cell Line, Tumor Genetics Androgens Humans Promoter Regions, Genetic Monoamine Oxidase Research Article Cell Proliferation Signal Transduction ets-Domain Protein Elk-1
DOI: 10.1371/journal.pgen.1008540 Publication Date: 2021-01-29T18:40:37Z
ABSTRACT
Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment, given the dependence cells on androgen and receptor (AR). However, tumors become ADT-resistant, there need to understand mechanism. One possible mechanism upregulation AR co-regulators, although only handful have been definitively linked disease. We previously identified Mediator subunit MED19 as an co-regulator, reported that depletion inhibits transcriptional activity growth androgen-insensitive LNCaP-abl cells. Therefore, we proposed would promote drive androgen-independent growth. Here, show stable overexpression in androgen-dependent LNCaP promotes under conditions deprivation. To delineate mechanism, determined transcriptomes cistromes control MED19-overexpressing also examined genome-wide H3K27 acetylation. selectively alters occupancy, acetylation, gene expression. Under deprivation, genes regulated by correspond ELK1, transcription factor binds N-terminus induce select target expression proliferation, genomic sites occupied are enriched for motifs associated with ELK1. Strikingly, upregulates monoamine oxidase A (MAOA), MAOA reduces occupy promoter, enhancing occupancy Furthermore, increases ELK1 at This suggests cooperates regulate acetylation MAOA, upregulating its driving independence study provides important insight into mechanisms cell low androgen, underscores importance MED19-MAOA axis this process.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (68)
CITATIONS (23)